References
- ThorpyMJKormanESpielmanAJGlovinskyPBDelayed sleep phase syndrome in adolescentsJ Adolesc Health Care19889122273335467
- CrowleySJAceboCCarskadonMASleep, circadian rhythms, and delayed phase in adolescenceSleep Med20078660261217383934
- OkawaMUchiyamaMCircadian rhythm sleep disorders: characteristics and entrainment pathology in delayed sleep phase and non-24-h sleep-wake syndromeSleep Med Rev200711648549617964201
- AugerRRBurgessHJEmensJSDeriyLVThomasSMSharkeyKMClinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015: An American Academy of Sleep Medicine Clinical Practice GuidelineJ Clin Sleep Med201511101199123626414986
- ShapiroDARenockSArringtonEAripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologyNeuropsychopharmacology20032881400141112784105
- MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200828215616518344725
- TakakiMUjikeHAripiprazole is effective for treatment of delayed sleep phase syndromeClin Neuropharmacol201437412312424992089
- MatsuiKTakaesuYInoueTInadaKNishimuraKEffect of aripiprazole on non-24-hour sleep-wake rhythm disorder comorbid with major depressive disorder: a case reportNeuropsychiatr Dis Treat2017131367137128579782
- MontiJMTorteroloPPandi PerumalSRThe effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophreniaSleep Med Rev201733517727321864
- StahlSMDopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptorsJ Clin Psychiatry2001621184184211775041
- KikuchiTTottoriKUwahodoY7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinon e (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activityJ Pharmacol Exp Ther199527413293367616416
- TadoriYForbesRAMcQuadeRDKikuchiTFunctional potencies of dopamine agonists and antagonists at human dopamine D(2) and D(3) receptorsEur J Pharmacol20116661–3435221658377
- TashiroTImprovement of a patient’s circadian rhythm sleep disorders by aripiprazole was associated with stabilization of his bipolar illnessJ Sleep Res201726224725028116759